Latest news
FDA Approves Replimune Skin Cancer Drug After Rejections - MedscapeMedscape · Fri, 07 Aug 2026 13:27:22 GMTReplimune wins on third try as FDA clears Tudriqev for melanoma - FirstWord PharmaFirstWord Pharma · Fri, 07 Aug 2026 00:57:10 GMTREPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? - TradingViewTradingView · Thu, 06 Aug 2026 21:37:21 GMTFDA Advisory Committee Backs RP1 for Advanced Melanoma - Cure TodayCure Today · Sun, 02 Aug 2026 14:37:01 GMTStephanie Kauffman: Awaiting the FDA's Final Decision on the IGNYTE Trial for Advanced Melanoma - OncodailyOncodaily · Sun, 02 Aug 2026 09:26:49 GMTREPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - TradingViewTradingView · Fri, 31 Jul 2026 10:45:28 GMTTwice-Rejected Advanced Melanoma Treatment Wins FDA Committee Vote - Oncology News CentralOncology News Central · Fri, 31 Jul 2026 07:00:00 GMTFDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study - Pharmaceutical ExecutivePharmaceutical Executive · Fri, 31 Jul 2026 07:00:00 GMT